Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Short Interest Down 36.0% in June

Posted by ABMN Staff on Jun 29th, 2024

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN – Get Free Report) was the target of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totalling 128,100 shares, a decrease of 36.0% from the May 31st total of 200,000 shares. Currently, 0.8% of the shares of the stock are short sold. Based on an average daily volume of 201,200 shares, the days-to-cover ratio is currently 0.6 days.

Inspira Technologies Oxy B.H.N. Price Performance

IINN opened at $1.38 on Friday. Inspira Technologies Oxy B.H.N. has a 1-year low of $0.76 and a 1-year high of $2.49. The company has a 50 day simple moving average of $1.96 and a two-hundred day simple moving average of $1.57. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.10.

Hedge Funds Weigh In On Inspira Technologies Oxy B.H.N.

An institutional investor recently bought a new position in Inspira Technologies Oxy B.H.N. stock. Armistice Capital LLC bought a new position in shares of Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,528,000 shares of the company’s stock, valued at approximately $1,620,000. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

Inspira Technologies Oxy B.H.N. Company Profile

(Get Free Report)

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.